Analysis of Compound Drugs Recorded in the National Drug Reimbursement List and Provincial Drug Re-imbursement Lists in 28 Provinces( Regions and Municipalities)of China
10.6039/j.issn.1001-0408.2017.28.03
- VernacularTitle:国家和28省(区、市)医保药品目录复合药收载情况分析
- Author:
Pengxiao ZHANG
1
;
Dan MEI
Author Information
1. 中国医学科学院北京协和医学院/北京协和医院药剂科
- Keywords:
Compound drug;
National drug reimbursement list;
Provincial drug reimbursement list;
Record
- From:
China Pharmacy
2017;28(28):3896-3900
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To provide reference for the selection and management of compound drugs. METHODS:The variet-ies and frequency of compound drugs recorded in the national drug reimbursement list and drug reimbursement list supplementary varieties in provinces (regions and municipalities) were statistically analyzed,and Spearman test method was used to conduct the correlation analysis for the variety and local economic development level. RESULTS:There were totally 126 varieties of compound drugs recorded in the national drug reimbursement list,covering 19 categories. The varieties of compound drugs in class B supple-mentary drug lists of 28 provinces (regions and municipalities) ranged from 19 to 50;for the supplementary lists of compound drugs in 24 provinces(regions and municipalities),the varieties ranged from 12 to 117. Almost 50% of the compound drugs were recorded in only 1 province(region and municipality),and most compound drugs recorded 1-4 time(s)in provinces(regions and municipalities). There was no significant relationship between the varieties number of supplementary compound drugs and the per capita GDP in a province(region and municipality)(P>0.05,r=-0.180). CONCLUSIONS:The supplementary variety of com-pound drugs in a region has little relationship with the local economic development level. The work progress of recoding the com-pound drugs varies a lot,with large differences in number and high dispersion. It is necessary to clarify the definition of compound drug at a national level,develop unified management policies,standardize the selection criteria for compound drugs and guarantee the clinical medication requirements of patients.
